KMT2A-rearranged B-cell acute lymphoblastic leukemia (KMT2A-r B-ALL) is an aggressive subtype of leukemia, characterized by high relapse rates, therapy resistance, and poor prognosis. Although CD19-targeted immunotherapies have significantly benefited patients with relapsed/refractory (R/R) disease, relapses remain common and long-term survival is especially poor in KMT2A-r B-ALL patients. We recently identified the membrane-bound proteoglycan NG2 (CSPG4) as direct transcriptional target of KMT2A fusions, with its expression associated with poor prognosis, early relapse, and glucocorticoid resistance in KMT2A-r B-ALL. However, the molecular mechanism underlying the aggressiveness of KMT2A-r B-ALL remains poorly understood. Here, we identify the α4 integrin subunit (ITGA4) and NG2 as a key biological axis contributing to leukemic aggressiveness. NG2 expression promotes proliferation and migration of KMT2A-r B-ALL cells and it is associated with Rho GTPase activity in an ITGA4-dependent manner. In vivo studies using immunodeficient mice demonstrated that ITGA4 and NG2 cooperate to promote leukemia progression as combined genetic ablation of both genes significantly delayed disease onset and prolonged survival. Notably, Natalizumab (NTZ) - an FDA/EMA-approved monoclonal antibody targeting ITGA4 - delayed leukemia progression and potentiated the efficacy of standard-of-care chemotherapy in KMT2A-r B-ALL patient-derived xenograft (PDX) models. Collectively, our findings define a novel ITGA4-NG2 signaling axis that drives the aggressiveness of KMT2A-r B-ALL and support the repurpose of NTZ as an adjuvant therapeutic strategy for this high-risk leukemia subtype.
Recent studies have emphasized the role of ADAMTS proteases in inflammation and immunity, particularly in the context of tumour progression. Since inflammatory cells can either constrain or promote tumour growth, understanding how ADAMTS proteases influence immune cell behaviour is crucial. Using syngeneic tumour models -B16F1 melanoma and Lewis Lung Carcinoma (LLC)- in Adamts1 knockout (Ats1-KO) mice, we observed model-specific outcomes underscoring the complexity of ADAMTS1 function in cancer. Transcriptomic and functional analyses revealed broad alterations in the matrisome and immune-related pathways across both tumour types. Strikingly, while tumour progression was impaired in B16F1-derived tumours, the LLC model -characterized by a stronger myeloid component- showed no dependency on Adamts1. To investigate this apparent resistance, we experimentally depleted macrophages and uncovered a profound functional defect in this population in Ats1-KO mice. In vitro assays confirmed reduced macrophage phagocytic activity. Mechanistically, we identified the transmembrane heparan sulfate proteoglycan syndecan-4 (SDC4), a known ADAMTS1 substrate, as a key mediator of this activity. Together, these findings reveal a previously unrecognized ADAMTS1-SDC4 axis that links extracellular matrix remodelling to macrophage phagocytosis, ultimately shaping tumour cell clearance and tumour progression.